Search

Displaying results 2021 - 2030 of 10000 in total
  1. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. … Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and

    Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking Antibody
  2. Drug

    Urokinase

    go.drugbank.com/drugs/DB00013
    ApprovedInvestigationalWithdrawn

    Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. … [A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]

    Products: UROKINASE KGCC INJ. 250000 IU FLAKON, 1 ADET, UROKINASE KGCC INJ. 500000 IU FLAKON, 1 ADET
  3. Drug

    Mentha arvensis leaf oil

    go.drugbank.com/drugs/DB16575
    Investigational

    Mixtures: TIGER BALM PLASTER-RD, TIGER MEDICATED PLASTER - RD
  4. Drug

    Sumatriptan

    go.drugbank.com/drugs/DB00669
    ApprovedInvestigational

    Sumatriptan is a serotonin receptor agonist commonly used to treat migraines and sometimes cluster headaches. … [L6793,L6796,L6799,L6805,L6808,L6811] Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.

    Mixtures: TRASS® TABLETA RECUBIERTA, TRASS® TABLETA RECUBIERTACategories: P-glycoprotein substrates, Heterocyclic Compounds, 2-Ring
  5. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over <sup>68</sup>Ga-labeled somatostatin analogs for positron emission tomography (PET). … [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution.

  6. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. … mavorixafor is being investigated in these conditions.

    Synonyms: N1-(1H-BENZIMIDAZOL-2-YLMETHYL)-N1-((S)-5,6,7,8-TETRAHYDROQUINOLIN-8-YL)-BUTANE-1,4-DIAMINE, 1,4-BUTANEDIAMINE, N-(1H-BENZIMIDAZOL-2-YLMETHYL)-N-((8S)-5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-Categories: MATE 1 Inhibitors, P-glycoprotein inhibitors
  7. Drug

    Desvenlafaxine

    go.drugbank.com/drugs/DB06700
    ApprovedInvestigational

    Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. … [L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: O-desmethylvenlafaxine
  8. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSynonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)
  9. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to _Clostridium difficile_ toxin B and neutralizes its effects. … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.

  10. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    [L39337] Sebelipase alfa is a recombinant form LAL approved for the treatment of LAL deficiency. … In addition, patients with LAL deficiency typically develop dyslipidemia, which itself contributes to a number of adverse cardiovascular outcomes.

    Products: KANUMA® 2 MG/ML CONCENTRADO PARA SOLUCION PARA INFUSION.